Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Jeon SY, Yhim HY, Kim HS, Kim JA, Yang DH, Kwak JY. Jeon SY, et al. Among authors: kim ja, kim hs. Korean J Intern Med. 2018 Nov;33(6):1169-1181. doi: 10.3904/kjim.2016.163. Epub 2018 Jan 8. Korean J Intern Med. 2018. PMID: 29295612 Free PMC article.
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY. Yhim HY, et al. Among authors: kim hj, kim sj, kim ja, kim js, kim ws. BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321. BMC Cancer. 2010. PMID: 20569446 Free PMC article.
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY. Yhim HY, et al. Among authors: kim sj, kim ja, kim js, kim ws. Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30. Int J Cancer. 2012. PMID: 21823120 Clinical Trial.
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Lee SE, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28. Am J Hematol. 2013. PMID: 23440689 Free article.
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Kim SH, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim dy, kim ja. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4. Haematologica. 2014. PMID: 24705186 Free PMC article. Clinical Trial.
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Park JS, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12. Leuk Lymphoma. 2016. PMID: 25947037
2,432 results